Identification
NameMagnesium carbonate
Accession NumberDB09481
TypeSmall Molecule
GroupsApproved
Description

Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label].

Structure
Thumb
SynonymsNot Available
External IDs C.I. 77713
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cepasium Tab 100mgTablet100 mgOralLaboratoires Cortunon Inc.1979-12-312002-08-23Canada
Humco Dewees CarminativeSuspension50 mg/mLOralHumco Holding Group. Inc.1998-03-25Not applicableUs
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acid Gone AntacidLiquidOralMajor2004-12-30Not applicableUs
Acid Gone Antacid Extra StrengthTablet, chewableOralMajor2014-06-06Not applicableUs
Aluminum Hydroxide and Magnesium CarbonateTablet, chewableOralSimpex Pharma Pvt. Ltd2012-11-15Not applicableUs
AntacidTablet, chewableOralMeijer Distribution1996-09-05Not applicableUs
Antacid - TabTabletOralSwiss Herbal Remedies Ltd.1996-09-042003-09-10Canada
Antacid Extra StrengthTablet, chewableOralRite Aid1997-08-07Not applicableUs
Aspirin Plus Stomach Guard Ext.stgth.capletTabletOralSterling Winthrop Inc.1994-12-311996-09-10Canada
Aspirin Plus Stomach Guard Extra StrengthTabletOralBayer Inc Consumer Care1995-12-311998-09-28Canada
Aspirin Plus Stomach Guard TabTabletOralSterling Winthrop Inc.1994-12-311996-09-10Canada
Aspirin With Stomach GuardTabletOralBayer Inc Consumer Care1997-10-012012-07-12Canada
Aspirin With Stomach Guard Extra Strength - TabTabletOralBayer Inc Consumer Care1997-07-072012-07-12Canada
Calcium and Magnesium TabTabletOralCountry Health Laboratories Ltd.1982-12-312001-07-27Canada
Cvs Health Extra Strength Heartburn Relief Antacid Original FlavorTablet, chewableOralCvs Health2015-08-27Not applicableUs
Equate Antacid Extra StrengthTablet, chewableOralWalmart Stores1999-09-07Not applicableUs
Equate Extra Strength AntacidTablet, chewableOralWalmart Stores1996-04-02Not applicableUs
EstomarolPowderOralLaboratorios Imperiales, S.A. De C.V.2011-05-11Not applicableUs
Extra Strength Heartburn ReliefSuspensionOralCvs Health2017-02-01Not applicableUs
Flexadyn TabTabletOralNutri Dyn Products Ltd.1976-12-311996-09-09Canada
Foamcoat AntacidTablet, chewableOralGuardian Drug Company2005-04-04Not applicableUs
Gavis-care AntacidSuspensionOralGericare Pharmaceuticals2000-01-01Not applicableUs
GavisconLiquidOralGlaxo Smith Kline Consumer Healthcare Holdings (Us) Llc2011-01-14Not applicableUs
Gaviscon Extra StrengthTablet, chewableOralGlaxo Smith Kline Consumer Heathcare Lp2011-06-13Not applicableUs
Gaviscon Heartburn Relief TabletsTabletOralSmithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.1996-12-311997-08-15Canada
Good Neighbor Pharmacy Antacid Extra StrengthTablet, chewableOralAmerisource Bergen2015-08-12Not applicableUs
InonGranuleOralSato Pharmaceutical1989-05-31Not applicableUs
Leader Antacid Extra StrengthTablet, chewableOralCardinal Health1996-10-23Not applicableUs
Maalox Antacid CapletsTabletOralRhone Poulenc Rorer1993-12-311996-09-09Canada
Magnebind 400 RxTablet, film coatedOralNephro Tech, Inc.1999-10-18Not applicableUs
Magnesium Comprime TabTabletOralHerbes Universelles Inc.1990-12-312009-07-15Canada
RenacidinSolutionIrrigationUnited Guardian, Inc.2016-02-01Not applicableUs
Riginic Antacid LiquidLiquidOralRij Pharmaceutical Corporation2013-04-03Not applicableUs
Rx Act Antacid Extra StrengthTablet, chewableOralH.E.B.1997-03-12Not applicableUs
Sohmed Acid ReducerTablet, chewableOralSOHM Inc.2013-08-25Not applicableUs
Stomachin AntacidCapsuleOralChang Kuo Chou Pharmaceutical Co. Ltd.2009-04-30Not applicableUs
Sunmark Antacid Extra StrengthTablet, chewableOralMc Kesson2003-08-21Not applicableUs
Tri-buffered Asa TabTabletOralZee Medical Inc1990-12-312009-07-30Canada
Categories
UNII0IHC698356
CAS number546-93-0
WeightAverage: 84.314
Monoisotopic: 83.969785764
Chemical FormulaCMgO3
InChI KeyZLNQQNXFFQJAID-UHFFFAOYSA-L
InChI
InChI=1S/CH2O3.Mg/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2
IUPAC Name
magnesium(2+) ion carbonate
SMILES
[Mg++].[O-]C([O-])=O
Pharmacology
Indication

Used as an over the counter antacid [5].

Structured Indications
Pharmacodynamics

Neutralizes acid in the stomach [5].

Mechanism of action

Magnesium carbonate reacts with hydrochloric acid in the stomach to form carbon dioxide and magnesium chloride thus neutralizing excess acid in the stomach [5].

TargetKindPharmacological actionActionsOrganismUniProt ID
Glutamate (NMDA) receptorProtein groupunknown
blocker
Humannot applicabledetails
Related Articles
Absorption

About 40-60% of magnesium is absorbed following oral administration [5]. Percent absorption decreases as dose increases.

Volume of distribution

Vd for magnesium is 0.2-0.4L/kg [5]. About 50% distributes to bone.

Protein binding

30% of magnesium is bound to proteins [5].

Metabolism

Magnesium does not appear to be metabolized in any way [5].

Route of elimination

Primarily eliminated in urine [5].

Half life

Half life of 27.7 hours reported with overdose of 400mEq of magnesium in an adult [5].

Clearance

Maximum magnesium clearance is directly proportional to creatinine clearance [5].

Toxicity

During overdose, magnesium impairs neuromuscular transmission resulting in weakness and hypoflexia [5].

Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium carbonate.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium carbonate.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineMagnesium carbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxyamphetamineMagnesium carbonate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
3,4-MethylenedioxymethamphetamineMagnesium carbonate may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMagnesium carbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Magnesium carbonate.Experimental, Illicit
AcepromazineMagnesium carbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineMagnesium carbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium carbonate.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magnesium carbonate.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium carbonate.Approved
AlimemazineMagnesium carbonate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolMagnesium carbonate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magnesium carbonate.Approved
AmphetamineMagnesium carbonate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit
AndrostenedioneThe bioavailability of 4-Androstenedione can be decreased when combined with Magnesium carbonate.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Magnesium carbonate.Investigational
AtazanavirMagnesium carbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium carbonate.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium carbonate.Approved, Investigational
BenzphetamineMagnesium carbonate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium carbonate.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Magnesium carbonate.Approved
BL-1020Magnesium carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium carbonate.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium carbonate.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Magnesium carbonate.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium carbonate.Approved
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium carbonate.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium carbonate.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium carbonate.Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium carbonate.Approved, Vet Approved
ChlorphentermineMagnesium carbonate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorpromazineMagnesium carbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlortetracyclineMagnesium carbonate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium carbonate.Approved, Investigational
CinoxacinMagnesium carbonate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
CiprofloxacinMagnesium carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Magnesium carbonate.Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium carbonate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magnesium carbonate.Approved
Clodronic AcidThe serum concentration of Clodronate can be decreased when it is combined with Magnesium carbonate.Approved, Investigational, Vet Approved
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium carbonate.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium carbonate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium carbonate.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium carbonate.Approved
DasatinibMagnesium carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium carbonate.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium carbonate.Approved
DemeclocyclineMagnesium carbonate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magnesium carbonate.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium carbonate.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium carbonate.Approved, Investigational, Vet Approved
DexmethylphenidateMagnesium carbonate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineMagnesium carbonate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionMagnesium carbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magnesium carbonate.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magnesium carbonate.Approved
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magnesium carbonate.Approved
Dipotassium phosphateMagnesium carbonate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineMagnesium carbonate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Magnesium carbonate.Approved
EnoxacinMagnesium carbonate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EquileninThe bioavailability of Equilenin can be decreased when combined with Magnesium carbonate.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Magnesium carbonate.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Magnesium carbonate.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium carbonate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium carbonate.Approved
Ferric CarboxymaltoseMagnesium carbonate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateMagnesium carbonate can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateMagnesium carbonate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium carbonate.Approved
FleroxacinMagnesium carbonate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium carbonate.Approved
FlumequineMagnesium carbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Magnesium carbonate.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium carbonate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium carbonate.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magnesium carbonate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magnesium carbonate.Approved
FluphenazineMagnesium carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magnesium carbonate.Approved, Withdrawn
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium carbonate.Approved
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium carbonate.Approved
Fluticasone propionateThe bioavailability of Fluticasone Propionate can be decreased when combined with Magnesium carbonate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium carbonate.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Magnesium carbonate.Approved, Investigational, Withdrawn
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium carbonate.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
GatifloxacinMagnesium carbonate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
GemifloxacinMagnesium carbonate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GrepafloxacinMagnesium carbonate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Magnesium carbonate.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
HydroxyamphetamineMagnesium carbonate may decrease the excretion rate of Hydroxyamphetamine hydrobromide which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium carbonate.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
IronMagnesium carbonate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMagnesium carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateMagnesium carbonate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidMagnesium carbonate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Magnesium carbonate.Approved
LevofloxacinMagnesium carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineMagnesium carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LomefloxacinMagnesium carbonate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Magnesium carbonate.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium carbonate.Approved
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magnesium carbonate.Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Magnesium carbonate.Approved, Investigational
MephedroneMagnesium carbonate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineMagnesium carbonate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium carbonate.Approved
MesoridazineMagnesium carbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethamphetamineMagnesium carbonate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Magnesium carbonate.Approved, Vet Approved
MethotrimeprazineMagnesium carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Methylene blueMagnesium carbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MethylphenidateMagnesium carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium carbonate.Experimental
MinocyclineMagnesium carbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Misoprostol.Approved
MMDAMagnesium carbonate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
MoricizineMagnesium carbonate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
MoxifloxacinMagnesium carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidMagnesium carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidMagnesium carbonate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Magnesium carbonate.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
NorfloxacinMagnesium carbonate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinMagnesium carbonate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl estrone can be decreased when combined with Magnesium carbonate.Investigational
OxytetracyclineMagnesium carbonate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium carbonate.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magnesium carbonate.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium carbonate.Approved
PazufloxacinMagnesium carbonate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinMagnesium carbonate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Magnesium carbonate.Approved
PerazineMagnesium carbonate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PerphenazineMagnesium carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineMagnesium carbonate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium carbonate.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Magnesium carbonate.Approved, Nutraceutical
Prasterone sulfateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Magnesium carbonate.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium carbonate.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium carbonate.Approved
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Magnesium carbonate.Experimental
ProchlorperazineMagnesium carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineMagnesium carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineMagnesium carbonate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrulifloxacinMagnesium carbonate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineMagnesium carbonate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineMagnesium carbonate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Magnesium carbonate.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Magnesium carbonate.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magnesium carbonate.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Magnesium carbonate.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
RitobegronMagnesium carbonate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinMagnesium carbonate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium carbonate.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium carbonate.Approved
Sodium glycerophosphateMagnesium carbonate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateMagnesium carbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium carbonate.Approved
SparfloxacinMagnesium carbonate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium carbonate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m Medronate can be decreased when it is combined with Magnesium carbonate.Approved
TemafloxacinMagnesium carbonate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineMagnesium carbonate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ThiethylperazineMagnesium carbonate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioridazineMagnesium carbonate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Tiludronic acidThe serum concentration of Tiludronate can be decreased when it is combined with Magnesium carbonate.Approved, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magnesium carbonate.Approved
TolevamerThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Polystyrene sulfonate.Approved
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magnesium carbonate.Approved, Vet Approved
TriethylenetetramineMagnesium carbonate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrifluoperazineMagnesium carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TriflupromazineMagnesium carbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinMagnesium carbonate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
UbidecarenoneThe serum concentration of Coenzyme Q10 can be decreased when it is combined with Magnesium carbonate.Experimental
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium carbonate.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. de Baaij JH: The art of magnesium transport. Magnes Res. 2015 Jul-Sep;28(3):85-91. doi: 10.1684/mrh.2015.0388. [PubMed:26446763 ]
  2. Jahnen-Dechent W, Ketteler M: Magnesium basics. Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14. doi: 10.1093/ndtplus/sfr163. [PubMed:26069819 ]
  3. Nikolaev MV, Magazanik LG, Tikhonov DB: Influence of external magnesium ions on the NMDA receptor channel block by different types of organic cations. Neuropharmacology. 2012 Apr;62(5-6):2078-85. doi: 10.1016/j.neuropharm.2011.12.029. Epub 2012 Jan 12. [PubMed:22261381 ]
  4. CDC NIOSH: MgCO3 [Link]
  5. Toxnet [Link]
External Links
ATC CodesV03AE04 — Calcium acetate and magnesium carbonateA02AA01 — Magnesium carbonateA06AD01 — Magnesium carbonate
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (129 KB)
MSDSDownload (79.7 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceGastroesophageal Reflux Disease1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHealthy Volunteers1
1RecruitingBasic ScienceGastroesophageal Reflux Disease1
4CompletedTreatmentEmergency / Indigestion / Pain1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
LiquidOral
TabletOral100 mg
SuspensionOral
Tablet, chewableOral
SuspensionOral50 mg/mL
GranuleOral
Tablet, film coatedOral
TabletOral
SolutionIrrigation
CapsuleOral
PowderOral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes at 350NIOSH [L781]
boiling point (°C)DecomposesNIOSH [L781]
water solubility0.1g/LNIOSH [L781]
Predicted Properties
PropertyValueSource
Water Solubility226.0 mg/mLALOGPS
logP0.52ALOGPS
logP0.25ChemAxon
logS0.21ALOGPS
pKa (Strongest Acidic)6.05ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.19 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity31.17 m3·mol-1ChemAxon
Polarizability3.52 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic acids and derivatives
Sub ClassOrganic carbonic acids and derivatives
Direct ParentOrganic carbonic acids
Alternative ParentsCarbonate salts / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
SubstituentsCarbonate salt / Carbonic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic salt / Organooxygen compound / Carbonyl group / Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptorsmagnesium salt, one-carbon compound, carbonate salt (CHEBI:31793 )

Targets

Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
blocker
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Nikolaev MV, Magazanik LG, Tikhonov DB: Influence of external magnesium ions on the NMDA receptor channel block by different types of organic cations. Neuropharmacology. 2012 Apr;62(5-6):2078-85. doi: 10.1016/j.neuropharm.2011.12.029. Epub 2012 Jan 12. [PubMed:22261381 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Protein serine/threonine kinase activity
Specific Function:
Essential ion channel and serine/threonine-protein kinase. Crucial for magnesium homeostasis. Has an important role in epithelial magnesium transport and in the active magnesium absorption in the gut and kidney. Isoforms of the type M6-kinase lack the ion channel region.
Gene Name:
TRPM6
Uniprot ID:
Q9BX84
Uniprot Name:
Transient receptor potential cation channel subfamily M member 6
Molecular Weight:
231705.935 Da
References
  1. Jahnen-Dechent W, Ketteler M: Magnesium basics. Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14. doi: 10.1093/ndtplus/sfr163. [PubMed:26069819 ]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
no
Actions
substrate
General Function:
Cation transmembrane transporter activity
Specific Function:
Not Available
Gene Name:
SLC41A3
Uniprot ID:
Q96GZ6
Uniprot Name:
Solute carrier family 41 member 3
Molecular Weight:
54766.1 Da
References
  1. de Baaij JH: The art of magnesium transport. Magnes Res. 2015 Jul-Sep;28(3):85-91. doi: 10.1684/mrh.2015.0388. [PubMed:26446763 ]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
no
Actions
substrate
General Function:
Magnesium ion transmembrane transporter activity
Specific Function:
Divalent metal cation transporter. Mediates transport of divalent metal cations in an order of Mg(2+) > Co(2+) > Mn(2+) > Sr(2+) > Ba(2+) > Cu(2+) > Fe(2+) (By similarity).
Gene Name:
CNNM2
Uniprot ID:
Q9H8M5
Uniprot Name:
Metal transporter CNNM2
Molecular Weight:
96622.35 Da
References
  1. de Baaij JH: The art of magnesium transport. Magnes Res. 2015 Jul-Sep;28(3):85-91. doi: 10.1684/mrh.2015.0388. [PubMed:26446763 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Protein serine/threonine kinase activity
Specific Function:
Essential ion channel and serine/threonine-protein kinase. Divalent cation channel permeable to calcium and magnesium. Has a central role in magnesium ion homeostasis and in the regulation of anoxic neuronal cell death. Involved in TNF-induced necroptosis downstream of MLKL by mediating calcium influx. The kinase activity is essential for the channel function. May be involved in a fundamental p...
Gene Name:
TRPM7
Uniprot ID:
Q96QT4
Uniprot Name:
Transient receptor potential cation channel subfamily M member 7
Molecular Weight:
212695.37 Da
References
  1. Jahnen-Dechent W, Ketteler M: Magnesium basics. Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14. doi: 10.1093/ndtplus/sfr163. [PubMed:26069819 ]
Drug created on November 30, 2015 12:10 / Updated on August 02, 2017 17:35